By Counterforce Health Team in Eylea / Lucentis (aflibercept / ranibizumab) —

Renewing Eylea and Lucentis Approval with Aetna CVS Health in Pennsylvania: Timeline, Documentation, and Appeal Options

Answer Box: Renewing Your Eylea or Lucentis Coverage

To renew Eylea (aflibercept) or Lucentis (ranibizumab) approval with Aetna CVS Health in Pennsylvania, start the process 60-90 days before your current authorization expires. You'll need updated OCT imaging, visual acuity measurements, and documentation of treatment response. Submit renewal requests through your ophthalmologist's office via Aetna's provider portal. Standard decisions take 30-45 days, but expedited reviews are available for urgent cases. If denied, Pennsylvania's Independent External Review Program has overturned over 50% of appealed denials in 2024.

Table of Contents

  1. Renewal Triggers: When to Start the Process
  2. Evidence Update: What Documentation You Need
  3. Renewal Packet: Must-Include Documents
  4. Timeline: Submission to Decision
  5. Bridge Options if Coverage Lapses
  6. Annual Changes to Monitor
  7. Appeals Process in Pennsylvania
  8. Personal Progress Tracker

Renewal Triggers: When to Start the Process

Most Aetna CVS Health prior authorizations for Eylea and Lucentis are approved for 12 months, though some plans may require more frequent renewals. Here's when to begin your renewal process:

Start Early Timeline:

  • 90 days before expiration: Check your current authorization end date
  • 60 days before expiration: Begin gathering updated clinical documentation
  • 30 days before expiration: Submit renewal request through your provider's office
Tip: Your ophthalmologist's office typically tracks authorization expiration dates, but confirm this during regular visits.

Warning Signs to Start Immediately:

  • You receive a letter about formulary changes
  • Your pharmacy reports coverage issues
  • You're approaching your annual injection limit
  • Your plan year is ending (many reset in January)

Evidence Update: What Documentation You Need

Successful renewals require current evidence of medical necessity and treatment response. Pennsylvania's Act 146 requires insurers to maintain accessible medical policies, so your provider can verify current requirements through Aetna's provider portal.

Clinical Response Documentation

Visual Function Assessment:

  • Current best-corrected visual acuity (BCVA) measurements
  • Comparison to baseline and previous visits
  • Amsler grid results if applicable

Structural Assessment:

  • Recent OCT (Optical Coherence Tomography) imaging
  • Comparison showing treatment response or disease stability
  • Fluorescein angiography if initially required

Treatment Adherence Record:

  • Documentation of all scheduled injections received
  • Any missed appointments and reasons
  • Intraocular pressure monitoring results

Safety Monitoring

Both Eylea and Lucentis require ongoing safety assessment:

  • Intraocular pressure checks before and after each injection
  • Endophthalmitis screening (any eye pain, redness, or vision changes)
  • Systemic adverse events documentation
  • Thromboembolic event screening for high-risk patients

Renewal Packet: Must-Include Documents

Your ophthalmologist's office will compile these essential documents for Aetna CVS Health:

Medical Necessity Letter Structure

Problem Statement:

  • Current diagnosis with ICD-10 codes
  • Disease severity and functional impact
  • Risk of vision loss without continued treatment

Prior Treatment Response:

  • Initial response to Eylea or Lucentis therapy
  • Functional improvements achieved
  • Anatomical improvements documented on imaging

Clinical Rationale:

  • Why continued therapy is medically necessary
  • Expected outcomes with treatment continuation
  • Risks of treatment discontinuation

Guideline Support:

  • FDA labeling for your specific indication
  • American Academy of Ophthalmology recommendations
  • Relevant clinical trial data

Required Supporting Documents

  • Current OCT imaging with measurements
  • Visual acuity flow sheet showing treatment response
  • Prior authorization history from other plans (if applicable)
  • Pharmacy records showing adherence to prescribed schedule

Timeline: Submission to Decision

Understanding Aetna CVS Health's decision timeline helps you plan effectively:

Standard Review Process

  • Day 0: Provider submits renewal request
  • Days 1-5: Aetna reviews for completeness
  • Days 5-30: Medical review and determination
  • Day 30-45: Final decision communicated

Expedited Review (When Applicable)

  • Available for: Immediate vision threat or treatment interruption risk
  • Timeline: Decision within 72 hours
  • Requirements: Provider must document urgency
Note: Expedited reviews are typically reserved for situations where treatment delay could cause irreversible vision loss.

Bridge Options if Coverage Lapses

If your Eylea or Lucentis authorization expires before renewal approval, several options can maintain treatment continuity:

Temporary Coverage Solutions

Avastin (Bevacizumab) Bridge:

  • Often covered as first-line therapy by Aetna
  • Costs approximately $50 per injection vs. $1,500+ for Eylea/Lucentis
  • American Academy of Ophthalmology notes comparable efficacy for most patients
  • Can serve as temporary treatment during authorization delays

Patient Assistance Programs:

  • Eylea Patient Assistance Program: Available for underinsured patients through Eylea.us
  • Manufacturer support: Can bridge gaps during authorization delays
  • Financial assistance: Payment plans available through specialty pharmacies

Medicare Considerations

If you have Medicare coverage:

  • Medicare Part B covers both medications after deductible
  • Eylea HD provides first-line access without prior authorization for Medicare Fee-for-Service patients
  • Patient responsibility: Approximately $300 per injection after meeting deductible

Annual Changes to Monitor

Aetna makes formulary changes on January 1 and October 1 each year. Key changes to watch:

Formulary Positioning

  • Step therapy requirements: May require Avastin trial first
  • Quantity limits: Injection frequency restrictions
  • Site of care requirements: Possible specialty pharmacy mandates

Plan Design Shifts

  • Prior authorization criteria updates
  • Medical policy revisions
  • Appeal process modifications
Important: Pennsylvania's Independence Blue Cross has implemented step therapy requiring Avastin trials before Eylea/Lucentis approval for new patients as of January 2025.

Appeals Process in Pennsylvania

Pennsylvania's Independent External Review Program, launched in January 2024, has proven highly effective for overturning insurance denials.

Internal Appeal (Required First Step)

  • Timeline: Must request within 180 days of denial
  • Process: Submit through Aetna member portal or by phone
  • Documentation: Include all supporting clinical evidence
  • Decision time: 30-45 days for standard appeals

Pennsylvania External Review

  • Eligibility: Must complete internal appeal first
  • Timeline: Request within 4 months of Final Adverse Benefit Determination
  • Success rate: Over 53% of appeals overturned in first six months of 2024
  • Submit at: pa.gov/reviewmyclaim or call 1-877-881-6388

Expedited External Review

  • When available: Life or health at serious risk
  • Timeline: Decision within 72 hours
  • Binding: Insurers must implement favorable decisions immediately

Counterforce Health specializes in turning insurance denials into successful appeals by identifying the specific denial basis and crafting evidence-backed rebuttals aligned to each plan's policies. Their platform helps patients and providers navigate complex prior authorization requirements and appeal processes more effectively.

Personal Progress Tracker

Use this framework to track your renewal progress:

Key Dates Tracker

  • Current authorization expires: ___________
  • Renewal process started: ___________
  • Documentation submitted: ___________
  • Decision expected by: ___________
  • Appeal deadline (if needed): ___________

Documentation Checklist

  • Current OCT imaging obtained
  • Visual acuity measurements updated
  • Treatment response documented
  • Medical necessity letter completed
  • Prior authorization form submitted
  • Follow-up scheduled

Contact Information

  • Aetna member services: Check your insurance card
  • Provider's prior authorization coordinator: ___________
  • Pennsylvania Insurance Department: 1-877-881-6388
  • Pharmacy contact: ___________

Common Renewal Challenges and Solutions

Challenge: Missing Clinical Documentation

Solution: Request records 30+ days in advance. Most offices need time to compile comprehensive treatment histories.

Challenge: Changed Medical Criteria

Solution: Review current Aetna medical policies through your provider. Criteria may have updated since your initial approval.

Challenge: Formulary Changes

Solution: If your medication moves to a higher tier or requires step therapy, your provider can request a formulary exception with clinical justification.

FAQ: Eylea and Lucentis Renewals

Q: How long do Aetna renewals typically take? A: Standard renewals take 30-45 days. Start the process 60-90 days before expiration to avoid treatment gaps.

Q: What if my medication is removed from the formulary? A: Your provider can request a formulary exception with clinical documentation showing medical necessity and lack of suitable alternatives.

Q: Can I appeal if my renewal is denied? A: Yes. Pennsylvania residents have strong appeal rights through the state's Independent External Review Program, which has overturned over 50% of appealed denials.

Q: Does step therapy apply to renewals? A: Generally no, if you're already successfully treated with Eylea or Lucentis. However, some plans may require documentation of why alternatives aren't suitable.

Q: What documentation do I need for an appeal? A: Include your denial letter, medical records showing treatment necessity, clinical response data, and relevant guidelines supporting continued therapy.

This information is for educational purposes only and is not medical advice. For specific coverage questions, contact Aetna CVS Health directly. For assistance with Pennsylvania insurance appeals, contact the Pennsylvania Insurance Department at 1-877-881-6388 or visit pa.gov/reviewmyclaim.

About Counterforce Health: Counterforce Health transforms insurance denials into targeted appeals by analyzing denial letters, plan policies, and clinical notes to craft evidence-backed rebuttals. The platform helps patients, clinicians, and specialty pharmacies navigate prior authorization requirements and appeal processes more effectively.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.